Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathology induced by leukemia inhibitory factor

B Ryffel1

  • 1Institut für Toxikologie, Eidgenössischen Technischen Hochschule Universität Zürich, Switzerland.

International Review of Experimental Pathology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Interleukin-22-deficiency and microbiota contribute to the exacerbation of Toxoplasma gondii-induced intestinal inflammation.

Mucosal immunology·2018
Same author

Interleukin-22-deficiency and microbiota contribute to the exacerbation of Toxoplasma gondii-induced intestinal inflammation.

Mucosal immunology·2018
Same author

A dietary flavone confers communicable protection against colitis through NLRP6 signaling independently of inflammasome activation.

Mucosal immunology·2017
Same author

Unravelling the roles of innate lymphoid cells in cerebral malaria pathogenesis.

Parasite immunology·2017
Same author

Neutrophilic NLRP3 inflammasome-dependent IL-1β secretion regulates the γδT17 cell response in respiratory bacterial infections.

Mucosal immunology·2017
Same author

The regulatory dendritic cell marker C1q is a potent inhibitor of allergic inflammation.

Mucosal immunology·2016
Same journal

Ultrasonic imaging of microscopic structures in living organs.

International review of experimental pathology·1996
Same journal

Measuring cytosolic Ca2+ in cells with fluorescent probes: an aid to understanding cell pathophysiology.

International review of experimental pathology·1996
Same journal

Simultaneous imaging of intracellular [Ca2+] and pH in single cells.

International review of experimental pathology·1996
Same journal

Optical studies of intracellular pH in kidney cells in vitro.

International review of experimental pathology·1996
Same journal

In situ studies of renal arteriolar function using the in vitro-perfused hydronephrotic rat kidney.

International review of experimental pathology·1996
Same journal

Tandem scanning confocal microscopic imaging of the living kidney.

International review of experimental pathology·1996
See all related articles

Leukemia inhibitory factor (LIF) shows broad biological effects, including hematopoiesis stimulation. However, in vivo studies reveal significant toxicity, indicating a narrow safety margin for therapeutic use.

Area of Science:

  • Biochemistry and Molecular Biology
  • Hematology
  • Regenerative Medicine

Background:

  • Leukemia inhibitory factor (LIF) is a pleiotropic glycoprotein with diverse biological functions.
  • LIF influences key cellular processes including growth, differentiation, and hematopoiesis.

Purpose of the Study:

  • To investigate the multifaceted activities of Leukemia inhibitory factor (LIF).
  • To evaluate the in vivo effects and safety profile of LIF, particularly concerning hematopoiesis.

Main Methods:

  • Review of existing literature on Leukemia inhibitory factor (LIF) activities.
  • Analysis of in vivo study outcomes in animal models (rodents and monkeys) following LIF administration.

Main Results:

Related Experiment Videos

  • Leukemia inhibitory factor (LIF) demonstrates potent effects on hematopoietic progenitor cells.
  • LIF exhibits bone regeneration, cachexia induction, acute-phase response in hepatocytes, and adipogenesis inhibition.
  • In vivo LIF treatment in animal models induced general toxicity, cachexia, acute-phase reactions, and hematopoiesis stimulation.

    • Conclusions:

    • Leukemia inhibitory factor (LIF) possesses significant therapeutic potential, especially for hematopoietic disorders.
    • The therapeutic application of LIF is constrained by a narrow safety margin due to observed systemic toxicity.